U.S. Capital Markets Stock News

Worthington Steel, Inc. has reported its third-quarter and nine-month results to February 28, 2026, with sales rising to US$769.8 million and US$2.51 billion respectively, while quarterly net income and earnings per share eased compared with the prior year, and the board declared a US$0.16 quarterly dividend payable June 26, 2026. An interesting contrast emerges as nine-month net income increased to US$66.0 million year on year even though third-quarter earnings and per-share results...

Why Star Bulk Carriers (SBLK) Is On Investors’ Radar Star Bulk Carriers (SBLK) has been drawing attention after recent share performance data showed mixed short term returns alongside stronger figures over the past 3 months and year, prompting closer inspection of its dry bulk shipping business. See our latest analysis for Star Bulk Carriers. At a share price of $23.72, SBLK has seen short term share price pressure with a 1 day return decline of 1.58%, while its 90 day share price return of...

If you are trying to figure out whether Lyft at around US$13.77 offers value or risk at this stage, the key is understanding what the current price actually reflects. The stock has returned 3.5% over the last week and 3.9% over the last month, while year to date it is down 30.4% and up 38.1% over the past year. This naturally raises questions about how expectations and risk are being priced in. These moves sit against a longer term backdrop where the 3 year return sits at 33.0% and the 5...

If you are wondering whether Novo Nordisk's current share price lines up with its fundamentals, this article walks through the key valuation angles that matter to you. The stock last closed at US$36.91, with recent returns of 0.4% over 7 days, a 4.3% decline over 30 days, a 29.5% decline year to date, and a 38.1% decline over the past year. This may signal changing views on its risk and reward profile. Recent news coverage has focused on Novo Nordisk's position in the pharmaceuticals and...

Wondering if MercadoLibre at around US$1,742 a share is still a quality opportunity or if the value case is fading? This article walks you through that question step by step. The stock has moved only 0.8% over the past week and is down 2.5% over 30 days, while the year to date return sits at an 11.7% decline and the 1 year return at a 4.6% decline, against a 35.6% gain over 3 years and 9.0% over 5 years. Recent headlines around MercadoLibre have focused on its role as a major player in Latin...

Those following along with Precision Optics Corporation, Inc. ( NASDAQ:POCI ) will no doubt be intrigued by the recent...

Investors who take an interest in Peapack-Gladstone Financial Corporation ( NASDAQ:PGC ) should definitely note that...

We wouldn't blame Sinclair, Inc. ( NASDAQ:SBGI ) shareholders if they were a little worried about the fact that Daniel...

We'd be surprised if Oil States International, Inc. ( NYSE:OIS ) shareholders haven't noticed that the Independent...

Even if it's not a huge purchase, we think it was good to see that Brian Roney, the President & CEO of Presurance...

FitLife Brands, Inc.'s ( NASDAQ:FTLF ) earnings announcement last week didn't impress shareholders. However, our...

Even if it's not a huge purchase, we think it was good to see that Junhua Wu, the Co-Founder of Baozun Inc...

If you are wondering whether Synopsys at around US$397.90 is priced for opportunity or already reflects high expectations, the key is to focus on what current valuation metrics are actually saying. The stock has seen a mixed run, with a 0.4% return over the last 7 days, a 9.0% decline over the past 30 days, a 17.2% decline year to date, but a 4.3% gain over the past year. These moves sit against a backdrop of ongoing interest in semiconductor design tools, AI related software and broader...

Gilead Sciences (NasdaqGS:GILD) has agreed to acquire German biotech Tubulis, adding next generation antibody drug conjugate technologies to its oncology pipeline. The deal includes Tubulis' clinical stage ADC assets and platforms, which will form a dedicated ADC research unit within Gilead. The acquisition aims to broaden Gilead's cancer treatment portfolio as it manages patent expiries and revenue pressure in other areas. Gilead Sciences, trading at around $138.8, has seen a 14.1% return...

In early April 2026, RBC Capital Markets reported that Hanover Insurance Group’s earnings growth is likely to slow, with 2025 expected to be the peak through 2027 as catastrophe losses normalize, pricing spreads moderate, and macroeconomic uncertainty weighs on the outlook. An interesting aspect of the report is management’s continued conservative reserving stance in challenging areas like Commercial Auto Liability, which may influence how investors assess future risk and capital...

If you are wondering whether Universal Technical Institute at around US$36.29 is priced for opportunity or already reflects the story you are buying into, this article walks through what the current valuation is actually indicating. The stock has returned 0.5% over the last 7 days, 3.7% over the last 30 days and 46.1% year to date, with a 39.1% return over the last year and a very large gain over 5 years. Recent coverage around Universal Technical Institute has focused on its role in the...

Dillard's (DDS) has introduced Cyd Morris x Gianni Bini, an exclusive limited-edition capsule collection with designer Cydney Morris. This move could interest investors watching how curated collaborations influence customer traffic and brand differentiation. See our latest analysis for Dillard's. Dillard's recent Cyd Morris x Gianni Bini launch comes as the share price sits at US$574.95, with short term share price returns weaker but a very large 5 year total shareholder return indicating...

Wondering if Credo Technology Group Holding at US$106.79 is still offering value after a strong run, or if you might be late to the party. The stock has seen very mixed recent returns, with a 13.8% gain over the last 7 days, a 2.8% decline over the last 30 days, a 25.4% decline year to date, and a 202.5% return over the past year. These swings have kept Credo on many watchlists, as investors react to ongoing developments around the company and the wider semiconductor space. Recent coverage...

If you are wondering whether Marriott International at around US$330.93 is offering value or asking you to pay up, you are not alone. It is a question worth unpacking carefully. The stock has returned 1.2% over the last 7 days, 2.2% over 30 days, 5.6% year to date, 58.2% over 1 year, 108.0% over 3 years and 131.0% over 5 years, so the current price reflects a long stretch of strong share performance. Recent coverage has focused on Marriott International's position within the broader travel...

If you are wondering whether Cummins at around US$556.78 is still offering value or already pricing in a lot of optimism, you are asking the right question. The stock has seen returns of 3.5% over the last 7 days, 3.3% over the last 30 days, 6.7% year to date, 112.3% over 1 year, 159.4% over 3 years and 140.9% over 5 years, which naturally raises questions about growth potential and changing risk perceptions. Recent attention around Cummins has focused on its role as a key industrial name in...

Tempus AI (TEM) is back in focus after announcing ALERT trial results showing its AI driven electronic health record alerts improved timely evaluations and valve interventions for patients with aortic stenosis and mitral regurgitation. See our latest analysis for Tempus AI. The ALERT trial news lands as the share price tells a mixed story, with a 3.5% 7 day share price return set against a 30 day share price return of 10.4% and a 90 day share price return of 32.9%. The 1 year total...

If you are wondering whether Sonoco Products at around US$54.06 is priced attractively or asking too much for future potential, you are in the right place. The stock has been relatively steady over the past week with a 0.1% decline. The 1 year return of 39.4% and year to date return of 21.8% suggest the share price has already moved a long way for current holders. Recent news around Sonoco Products has focused on its position in the packaging sector and how investors are viewing its long...

Cyber.AI launch puts Accenture (ACN) at the center of AI security and dividend timing Accenture (ACN) has launched Cyber.AI, a Claude powered security solution aimed at continuous AI driven cyber operations, just as the stock approaches an ex dividend date that may focus investors on both income and innovation. See our latest analysis for Accenture. The Cyber.AI launch and upcoming dividend arrive after a tougher stretch for the stock, with a 30 day share price return of 8.23% and a 1 year...

AbbVie is launching Humira on the TrumpRx platform at an 86% discount as part of a new White House agreement to improve drug accessibility and reduce prices. The move marks a significant change in how one of the most widely used autoimmune drugs is priced and distributed to patients in the US. This corporate action extends AbbVie’s role beyond product development into direct collaboration with federal policy on affordable medication. For investors tracking AbbVie, ticker NYSE:ABBV, the...